ISS GVS PHARMA LTD.



May 11, 2021

To

The Manager, Listing Department National Stock Exchange of India Ltd.

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai-400 051 Symbol: BLISSGVS

The General Manager, Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001

Scrip Code: 506197

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Tuesday, May 11, 2021

We would like to inform you that, the Board Meeting of the Company was held today i.e. Tuesday, May 11, 2021 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters:

- 1. The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report of the auditors. The copy of said financial results and audit reports are enclosed herewith as 'Annexure - 1';
- 2. Declaration of unmodified opinion for annual audited standalone and consolidated financial results for the year ended March 31, 2021 in accordance with Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed herewith as 'Annexure - 2';
- 3. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/each for the financial year ended March 31, 2021, subject to approval of the shareholders in the forthcoming Annual General Meeting of the Company;
- 4. Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2021-22. The brief profile of the internal auditor is enclosed herewith as 'Annexure-3';

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

ISS GVS PHARMA LTD.



5. Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019' ('Bliss GVS ESOP-2019') to the eligible employees under the said Plan, pursuant to exercise of stock options granted thereunder.

Consequent to the aforesaid allotment, Issued, subscribed & paid-up share capital of the Company has increased as under:

From	То
10,31,46,672 equity shares of Re.1 each	10,33,57,172 equity shares of Re.1 each
aggregating Rs. 10,31,46,672/-	aggregating Rs. 10,33,57,172 /-

In terms of Regulation 10(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014 (SEBI SBEB Regulations) read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 the details of shares allotted as above are given in 'Annexure-4';

- 6. Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company for a further period of 5 years with effect from 26th May, 2021 to 25th May, 2026, subject to the approval of members in the ensuing Annual General Meeting. The brief profile of Mr. Santosh Laxman Parab is enclosed herewith as 'Annexure-5';
- 7. Resignation of Mr. S N Kamath from the position of Managing Director as well as membership from all committees of board of the Company with immediate effect i.e. May 11, 2021;
- 8. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company for a period of Three years with effect from 11th May, 2021 to 10th May, 2024, subject to the approval of members in the ensuing Annual General Meeting. The brief profile is enclosed herewith as 'Annexure-6'.
- 9. The Board reconstituted the following committees:
 - a. Audit Committee
 - b. Corporate Social Responsibility Committee

The Reconstitution is enclosed herewith as 'Annexure -7'.



Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory:

Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

SS GVS PHARMA LTD.



The meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 07:20 p.m.

Kindly take the above information on your record and acknowledge.

Thanking you.

Your Faithfully,

For Bliss GVS Pharma Limited

Vipul B. Th Chief Financi

Encl: As above

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory:

Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com



<u>'Annexure - 4'</u> Regulation 10(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014

Company Name and address of Registered Office Name of the Stock Exchanges on which the Company's shares are listed	Add: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400072 BSE Limited The National Stock Exchange of India
Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2014 with Stock Exchange	Limited 14/02/2020
Filing Number, if any	Application No: BSE - 106063 NSE - 23188 In-Principle Approval Letter: BSE: DCS/FL/DS/ESOP-IP/542/2019-20 dated February 27, 2020 NSE: NSE/LIST/23188 dated March 04, 2020
Title of the Scheme pursuant to which shares are issued, if any	Bliss GVS Pharma Limited-Employee Stock Option Plan 2019
Kind of security to be listed	Equity Shares
Par value of the shares	Rs. 1/- Per Share
Date of issue of shares	May 11, 2021
Number of shares issued	2,10,500
Share Certificate No., if applicable	Not Applicable
Distinctive number of the share, if applicable	10,31,46,672 to 10,33,57,172 (both inclusive)
ISIN Number of the shares if issued in Demat	INE416D01022
Exercise price per share	Rs.43 per share
Premium per share	Rs.42 per share





Total Issued shares after this issue	10,33,57,172
Total Issued share capital after this issue	Rs.10,33,57,172/-
Details of any lock-in on the shares	Lock in for a period of 6 (six) months from the date of allotment of Equity Shares.
Date of expiry of lock-in	10 th November, 2021
Whether shares identical in all respects to existing shares if not, when will they become identical?	All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
Details of listing fees, if payable	Not applicable

Relevant disclosures as per SEBI circular CIR/CFD/CMD/4/2015 dated September 9, $2015\,$

Options Vested	690,250 Equity Shares
Time within which option may be	Within a period of 6 (Six) months from the
exercised	date of vesting of such options.
Options exercised	2,10,500 Equity Shares
Money realized by exercise of options	Rs.90,51,500/-
The total number of shares arising as	2,10,500 Equity Shares
result of exercise of option	
Options lapsed	5
Diluted earnings per share pursuant to	Rs.6.53 per share
issue of equity shares on exercise of	
options	
Whether the scheme is in terms of SEBI	Yes
(SBEB) Regulations, 2014	

